Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2195-2201

  Yan, Li ^a   Li, Li ^a   Li, Qinghuai ^a   Di, Wang ^a   Shen, Wei ^a   Zhang, Linlei ^a   Guo, Hao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

FGF2; Papillary thyroid cancer; PSTAT3; STAT3; VEGF C

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; PHOSPHORYLATED STAT3 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID PAPILLARY CARCINOMA; UPREGULATION; WESTERN BLOTTING;

EID: 84928251816     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2409     Document Type: Article

References (38)

1. Kent WD, Hall SF, Isolato PA, Houlden RL, George RL and Groome PA: Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177: 1357-1361, 2007.
2. Alvarado R, Sywak MS, Delbridge L and Sidu SB: Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity? Surgery 145: 514-518, 2009.
3. Lee YS, Lim YS, Lee JC, Wang SG, Kim IJ and Lee BJ: Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: preliminary report. World J Surg 34: 2558-2563, 2010.
4. Wan H, Zhang B, Liu S, et al: Preliminary study of patterns of level IIb lymph node metastasis in papillary thyroid carcinoma. Zhonghua Er Bai Yan Hou Tou Jing Wai Ke Za Zhi 49: 27-30, 2014 (In Chinese).
5. Eun YG, Lee YC and Kwon KH: Predictive factors of contralateral paratracheal lymph node metastasis in papillary thyroid cancer: prospective multicenter study. Otolaryngol Head Neck Surg 150: 210-215, 2014.
6. Cooper DS, Doherty GM, Haugen BR, et al; American Thyroid Association Guidelines Taskforce: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109-142, 2006.
7. Frasoldati A, Toschi E, Zini M, et al: Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. Thyroid 9: 105-111, 1999.
8. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS and Kim EK: Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 193: 871-878, 2009.
9. Kim MJ, Kim EK, Kim BM, et al: Thyroglobulin measurement in fine-needle aspirate washouts: the criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol (Oxf) 70:145-151, 2009.
10. Pacini F, Fugazzola L, Lippi F, et al: Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 74: 1401-1404, 1992.
11. Zhang Z, Bai Y, Li P, Zhao J, Wang Y, Sun L and Tang J: Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinonma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 27: 1265-1268, 2013 (In Chinese).
12. Slattery ML, John EM, Stern MC, et al: Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat 140: 587-601, 2013.
13. Jebreel A, England J, Bedford K, Murphy J, Karsai L and Atkin S: Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88: 271-277, 2007.
14. Dralle H and Machens A: Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab 22: 971-987, 2008.
15. Sakorafas GH, Sampanis D and Safioleas M: Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol 19: e57-e70, 2010.
16. Bournazou E and Bromberg J: Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT 2: e23828, 2013.
17. Voskas D, Ling LS and Woodgett JR: Signals controlling un-differentiated states in embryonic stem and cancer cells: role of the phosphatidylinositol 3' kinase pathway. J Cell Physiol 229: 1312-1322, 2014.
18. Zouein FA, Duhé RJ and Booz GW: JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors 29: 245-252, 2011.
19. Kamran MZ, Patil P and Gude RP: Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int 2013: 421821, 2013.
20. Feng Y, Ke C, Tang Q, et al: Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 5: e1088, 2014.
21. Pandurangan AK and Esa NM: Signal transducer and activator of transcription 3 - a promising target in colitis-associated cancer. Asian Pac J Cancer Prev 15: 551-560, 2014.
22. Zhang J, Gill A, Atmore B, Johns A, Delbridge L, Lai R and McMullen T: Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. Int J Clin Exp Pathol 4: 356-362, 2011.
23. Kawakami Y, Yaguchi T, Sumimoto H, et al: Improvement of cancer immunotherapy by combing molecular targeted therapy. Front Oncol 3: 136, 2013.
24. Gu L, Talati P, Vogiatzi P, et al: Pharmacological suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 13: 1246-1258, 2014.
25. Farren MR, Carlson LM, Netherby CS, et al: Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance. Sci Signal 7: ra16, 2014.
26. Iwata-Kajihara T, Sumimoto H, Kawamura N, et al: Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol 187: 27-36, 2011.
27. Chen Y, Wang J, Wang X, et al: STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer 16: 40-49, 2013.
28. Bednarek I, Sypniewski D, Gawlik N, Galilejczyk A and Goraus K: The efficiency of silencing expression of the gene coding STAT3 transcriptional factor and susceptibility of bladder cancer cells to apoptosis. Contemp Oncol (Pozn) 16: 316-321, 2012.
29. Couto JP, Daly L, Almeida A, et al: STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci USA 109: E2361-E2370, 2012.
30. Dong L, Li Y, Cao J, et al: FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. Cell Death Differ 19: 616-622, 2012.
31. Coleman SJ, Chioni AM, Ghallab M, et al: Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med 6: 467-481, 2014.
32. Lee HJ, Seo AN, Park SY, et al: Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol 21: 1561-1568, 2014.
33. Meng QH, Xu E, Hildebrandt MA, et al: Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem 60: 222-232, 2014.
34. Huang C, Huang R, Chang W, et al: The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma 59: 52-61, 2012.
35. Yu XM, Lo CY, Chan WF, Lam KY, Leung P and Luk JM: Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 11: 8063-8069, 2005.
36. Karaca Z, Tanriverdi F, Unluhizarci K, et al: VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 164: 277-284, 2011.
37. Hai-yun S, Deng-ting C and Shou-yi D: Preoperative and postoperative serum VEGF-C levels and its clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26: 903-904, 2010 (In Chinese).
38. Emoto N, Onose H, Sugihara H, Minami S, Shimizu K and Wakabayashi I: Fibroblast growth factor-2 free from extracellular matrix is increased in papillary thyroid carcinomas and Graves' thyroids. Thyroid 8: 491-497, 1998.